IP Verse

Treatment Of Excessive Menstrual Bleeding Associated With Uterine Fibroids - EP2731613

The patent EP2731613 was granted to Preglem on Aug 30, 2017. The application was originally filed on Jul 12, 2012 under application number EP12755904A. The patent is currently recorded with a legal status of "Revoked".

EP2731613

PREGLEM
Application Number
EP12755904A
Filing Date
Jul 12, 2012
Status
Revoked
Jul 10, 2020
Grant Date
Aug 30, 2017
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (5)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

ACCORD HEALTHCAREMay 30, 2018ACCORD HEALTHCAREADMISSIBLE
ZENTIVA KSMay 30, 2018HOFFMANN EITLEADMISSIBLE
GENERICS UKMay 29, 2018TER MEER STEINMEISTER & PARTNERADMISSIBLE
HELMMay 29, 2018UEXKULL & STOLBERGADMISSIBLE
HEXALMay 29, 2018MAIWALDADMISSIBLE

Patent Citations (14) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
INTERNATIONAL-SEARCH-REPORTUS2007213306
INTERNATIONAL-SEARCH-REPORTUS2009118253
INTERNATIONAL-SEARCH-REPORTUS2009192130
INTERNATIONAL-SEARCH-REPORTUS6451780
OPPOSITIONEP1602662
OPPOSITIONUS2007213306
OPPOSITIONUS2009192130
OPPOSITIONWO2006010097
OPPOSITIONWO2007038796
OPPOSITIONWO2007103510
OPPOSITIONWO2008083192
OPPOSITIONWO2008129396
OPPOSITIONWO2009095418
OPPOSITIONWO2013008202

Non-Patent Literature (NPL) Citations (31) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
EXAMINATION- Gary P Siskin ET AL, "Uterine Artery Embolization for the Treatment of Adenomyosis: Clinical Response and Evaluation with MR Imaging", AJR. American Journal of Roentgenology, (20010801), vol. 177, no. 2, pages 297 - 302, XP055225972-
EXAMINATION- JEAN-PIERRE PELAGE ET AL, "Midterm Results of Uterine Artery Embolization for Symptomatic Adenomyosis: Initial Experience1", RADIOLOGY, US, (200503), vol. 234, no. 3, doi:10.1148/radiol.2343031697, ISSN 0033-8419, pages 948 - 953, XP055225886
INTERNATIONAL-SEARCH-REPORT- SPITZ IRVING M, "Progesterone receptor antagonists", CURRENT OPINION IN INVESTIGATIONAL DRUGS, PHARMAPRESS, US, (20061001), vol. 7, no. 10, ISSN 1472-4472, pages 882 - 890, XP009110067 [Y] 1-34 * page 886, column 1, paragraph 1 - column 2, paragraph 1 * * table 1 *-
INTERNATIONAL-SEARCH-REPORT- SAMUEL ET AL, "Future research into abnormal uterine bleeding", BAILLIERE'S BEST PRACTICE AND RESEARCH. CLINICAL OBSTETRICS ANDGYNAECOLOGY, BAILLIERE TINDALL, LONDON, GB, (20071201), vol. 21, no. 6, doi:10.1016/J.BPOBGYN.2007.03.018, ISSN 1521-6934, pages 1023 - 1040, XP022367522 [Y] 1-34 * page 1030, column 4 - page 1031, column 2 *
INTERNATIONAL-SEARCH-REPORT- SANKARAN S ET AL, "Medical management of fibroids", BAILLIERE'S BEST PRACTICE AND RESEARCH. CLINICAL OBSTETRICS ANDGYNAECOLOGY, BAILLIERE TINDALL, LONDON, GB, vol. 22, no. 4, doi:10.1016/J.BPOBGYN.2008.03.001, ISSN 1521-6934, (20080801), pages 655 - 676, (20080512), XP022731372 [Y] 1-34 * page 666, paragraph 3 - page 668, paragraph 1 *
INTERNATIONAL-SEARCH-REPORT- AMBAT S ET AL, "Uterine artery embolization versus laparoscopic occlusion of uterine vessels for management of symptomatic uterine fibroids", INTERNATIONAL JOURNAL OF GYNECOLOGY AND OBSTETRICS, NEW YORK, NY, US, vol. 105, no. 2, doi:10.1016/J.IJGO.2009.01.006, ISSN 0020-7292, (20090501), pages 162 - 165, (20090220), XP026038246 [Y] 1-34 * abstract * * figures 1,3 *
INTERNATIONAL-SEARCH-REPORT- MILLER ET AL, "Unmet Therapeutic Needs for Uterine Myomas", JOURNAL OF MINIMALLY INVASIVE GYNECOLOGY, ELSEVIER, NL, vol. 16, no. 1, doi:10.1016/J.JMIG.2008.08.015, ISSN 1553-4650, (20090101), pages 11 - 21, (20081224), XP025839205 [Y] 1-34 * abstract * * page 11, column 1, paragraph 1 * * page 12, column 2, paragraph 3 - page 13, column 1, paragraph 3 * * page 15, column 1, paragraph 1 - page 19, column 1, paragraph 1 * * table 3 *
INTERNATIONAL-SEARCH-REPORT- CHWALISZ K ET AL, "Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis", ENDOCRINE REVIEWS, THE ENDOCRINE SOCIETY, US, vol. 26, no. 3, doi:10.1210/ER.2005-0001, ISSN 0163-769X, (20050501), pages 423 - 438, (20050427), XP002527456 [Y] 1-34 * abstract * * page 424, column 2, paragraph 2 - page 425, column 1, paragraph 1 * * page 433, column 1, paragraph 2 - page 434, column 1, paragraph 1 *
OPPOSITION- Anonymous, "Uterine fibroids", Merck Manual, Health Care Professionals, Gynecology and Obstetrics, (20140915), pages 1 - 9, XP055497251-
OPPOSITION- DR. RICHARD KING et al., "Management of fibroids should be tailored to the patient", The Practitioner, (20110300), vol. 255, no. 1738, pages 19 - 23, XP055492775-
OPPOSITION- H.A. GOLDFARB, "Myolysis Revisited", JSLS, Journal of the Society of Laparoendoscopic Surgeons, (20080000), vol. 12, pages 426 - 430, XP055492765-
OPPOSITION- "ICH E9 Note for Guidance on Statistical Principles for Clinical Trials", eurpean medicines agency, (19980900), pages 1 - 37, XP055492770-
OPPOSITION- KING et al., "managment of fibroids should be tailored to the patient", The Practitioner, (20110300), vol. 255, no. 1738, pages 19 - 23, XP055492775-
OPPOSITION- LEFEBVRE et al., "THE MANAGEMENT OF UTERINE LEIOMYOMAS", J Obstet Gynaecol Can, (20030500), vol. 25, no. 5, pages 1 - 10, XP055492778-
OPPOSITION- LEFEBVRE et al., "The Management of Uterine Leiomyomas", SOGC Clinical Practice Guidelines, (20030500), pages 1 - 10, XP055492778-
OPPOSITION- PEDRO A. ORIHUELA, "Drug evaluation: Ulipristal, a progesterone receptor antagonist as a contraceptive and for the treatment of uterine fibroids", Current Opinion in In- vestigational Drugs, (20070000), pages 859 - 866, XP009115744-
OPPOSITION- "Uterine artery embolisation for fibroids", NICE Interventional procedures guidance, (20101124), pages 1 - 7, URL: https://www.nice.org.uk/guidance/ipg367/resources/uterine-artery-embolisation-for-fibroids-pdf-1899867699199429, XP055494331-
OPPOSITION- "UTERINE FIBROIDS:", Merck Manual Professional, Uterine Fibroids, Gynecology and Obstetrics, (20080000), pages 1 - 3, XP002525139-
OPPOSITION- VEASY C. BUTTRAM et al., "Uterine Leiomyomata: etiology, symptomatology, and Management", Fertility and Sterility, (19810000), vol. 36, no. 4, pages 433 - 445, XP055497255-
OPPOSITION- L.K. NIEMAN et al., "Efficacy and tolerability of CDB-2914 treatment for symptomatic uterine fibroids: a randomized, double-blind, placebo-controlled, phase lib study", Fertility and Sterility®, (20110200), vol. 95, no. 2, pages 767 - 772 , 772.el and 772.e2, XP055129509
OPPOSITION- NIEMAN et al., "Efficacy and tolerability of CDB-2914 treatment for symptomatic uterine fibroids: a randomized, double-blind, placebo-controlled, phase IIb study", Fertility & Sterility, (20110000), vol. 95, no. 2, pages 767 - 772, XP055129509
OPPOSITION- NIEMAN et al., "Efficacy and tolerability of CDB-2914 treatment for symptomatic uterine fibroids: a randomized, double-blind, placebo-controlled, phase IIb study", Fertility & Sterility, (20110200), vol. 95, no. 2, pages 767 - 772, XP055129509
OPPOSITION- SREEKRISHNAKIRAN AMBAT et al., "Uterine Artery Embolization Versus Laparoscopic Occlusion of Uterine Vessels for Management of Symptomatic Uterine Fibroids", International Journal of Gynecology and Obstetrics, (20090000), vol. 105, no. 2, pages 162 - 165, XP026038246
OPPOSITION- BARBARA J. ATTARDI et al., "In vitro antiprogestational/antiglucocorticoid activity and progestin and glucocorticoid receptor binding of the putative metabolites and syn- thetic derivatives of CDB-2914, CDB-4124, and mifepristone", JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOL, (20040000), vol. 88, no. 3, pages 277 - 288, XP009115739
OPPOSITION- DIANA L. BLITHE et al., "Development of the selective progesterone receptor modula- tor CDB-2914 for clinical indications", STEROIDS, (20030000), vol. 68, pages 1013 - 1017, XP004479951
OPPOSITION- NATHALIE CHABBERT-BUFFET et al., "Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications", Human Reproduction Update, (20050000), vol. 11, no. 3, pages 293 - 307, XP008140594
OPPOSITION- ERIC D. LEVENS, "CDB-2914 for Uterine Leiomyomata Treatmen t", Obstetrics & Gynecology, (20080000), vol. 111, no. 5, pages 1129 - 1136, XP008106062
OPPOSITION- S RASHID et al., "The Effects of Uterine Arteiy Embolisation and Surgical Treatment on Ovarian Function in Women with Uterine Fibroids", BJOG An International Journal of Obstetrics and Gynaecology, (20100000), vol. 117, no. 8, pages 985 - 989, XP055492820
OPPOSITION- S RASHID et al., "The effects of uterine artery embolisation and surgical treatment on ovarian function in women with uterine fibroids", BJOG An International Journal of Obstetrics and Gynaecology, (20100500), pages 985 - 989, XP055492820
OPPOSITION- ERIC D. LEVENS et al., "82 Ranomized, Placebo-controlled, Double Blind, Parallel Trial of the Novel Selective Progesterone Receptor Modulator, CDB-29-14", Reproductive Sciences Poster Sessions, (20070100), vol. 14, no. 1, pages 79A - 80A, XP055497228
OPPOSITION- NATHALIE CHABBERT-BUFFET et al., "Effects of the Progesterone Receptor Modulator VA2914.... Placebo-Controlled Trial", The Endocrine Society, (20070900), vol. 92, no. 9, pages 3582 - 3589, XP055374368

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents